ASH 2020 Highlights
Belantamab Induces Clinically Meaningful Responses in Heavily Pretreated Patients with Multiple Myeloma
A post-hoc analysis of a pivotal clinical trial showed that belantamab mafodotin-blmf (Blenrep), a first-in-class antibody–drug conjugate targeting B-cell maturation antigen, induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Financial toxicity can have a negative effect on outcomes for patients with cancer. However, findings from a recent pilot study revealed that a comprehensive intervention focused on the financial aspects of care significantly improved quality of life for patients with hematologic malignancies.
Approximately two-thirds of patients with chronic-phase chronic myeloid leukemia (CML) achieved a major cytogenetic response to the novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI) vodobatinib, regardless of whether they had received previous treatment with ponatinib (Iclusig), according to findings from a recent phase 1 clinical trial.
Results 1 - 3 of 3